Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Common Equity (2016 - 2025)

Standard Biotools (LAB) has disclosed Common Equity for 16 consecutive years, with $399.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Common Equity fell 18.33% to $399.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $399.7 million, a 18.33% decrease, with the full-year FY2024 number at $471.7 million, up 418.62% from a year prior.
  • Common Equity was $399.7 million for Q3 2025 at Standard Biotools, down from $424.5 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $577.3 million in Q1 2024 to a low of -$148.1 million in Q4 2023.
  • A 5-year average of $163.4 million and a median of $99.3 million in 2021 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: crashed 539.35% in 2023, then soared 694.23% in 2024.
  • Standard Biotools' Common Equity stood at $94.6 million in 2021, then crashed by 186.12% to -$81.5 million in 2022, then tumbled by 81.73% to -$148.1 million in 2023, then soared by 418.62% to $471.7 million in 2024, then dropped by 15.28% to $399.7 million in 2025.
  • Per Business Quant, the three most recent readings for LAB's Common Equity are $399.7 million (Q3 2025), $424.5 million (Q2 2025), and $454.6 million (Q1 2025).